Search for dissertations about: "BCR ABL1"
Showing result 1 - 5 of 13 swedish dissertations containing the words BCR ABL1.
-
1. Molecular and functional studies of the BCR/ABL1 fusion gene
Abstract : The BCR/ABL1 fusion gene is associated with chronic myeloid leukemia and a subgroup of acute lymphoblastic leukemia. The general aim of this thesis was to increase the understanding of BCR/ABL1-induced leukemogenesis by molecular and functional studies of this fusion gene. READ MORE
-
2. Characterization of Genetic Abnormalities at Disease Progression of Chronic Myeloid Leukemia
Abstract : Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the translocation t(9;22)(q34;q11) and progresses from a relatively indolent chronic phase (CP) to an accelerated phase (AP) and finally to the more aggressive blast crisis (BC). The general aim of this thesis was to identify and characterize genetic abnormalities occurring at disease progression of CML using molecular cytogenetic, molecular genetic, and bioinformatic analyses. READ MORE
-
3. The Wilms' tumor gene 1 (WT1) and leukemia -new insights and further complexity
Abstract : The Wilms tumor gene 1 (WT1) encodes a zinc-finger containing transcription factor which is highly expressed in immature hematopoietic progenitor cells. A high expression of WT1 and the presence of somatic mutations in acute leukemia indicate a role for WT1 in the pathogenesis of leukemia. READ MORE
-
4. Stem and progenitor cell involvement in acute lymphoblastic leukemia
Abstract : Leukemic stem cells (LSCs) share the capacity of self renewal and extensive proliferation with normal hematopoietic stem cells (HSCs), and are therefore obvious targets for therapy. As such, they need to be identified and characterized in order to elucidate what drives them, and what separates them from their normal counterparts. READ MORE
-
5. Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia
Abstract : Chronic myeloid leukemia (CML) is caused by the transformation of a primitive hematopoietic cell by the BCR/ABL1 fusion gene that is formed through the chromosomal translocation t(9;22). CML is currently successfully treated with tyrosine kinase inhibitors targeting the ABL1 kinase domain. READ MORE